Atara Biotherapeutics (NASDAQ:ATRA) Shares Gap Up to $7.74

Atara Biotherapeutics, Inc. (NASDAQ:ATRAGet Rating)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $7.74, but opened at $8.08. Atara Biotherapeutics shares last traded at $7.64, with a volume of 1,538 shares trading hands.

A number of research firms have issued reports on ATRA. JPMorgan Chase & Co. cut their target price on shares of Atara Biotherapeutics from $27.00 to $22.00 and set an “overweight” rating on the stock in a research report on Monday, March 28th. Canaccord Genuity Group lowered their target price on Atara Biotherapeutics from $78.00 to $67.00 in a research note on Tuesday, March 1st. StockNews.com assumed coverage on Atara Biotherapeutics in a research note on Thursday, March 31st. They set a “sell” rating for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $31.00 price target on shares of Atara Biotherapeutics in a research note on Thursday, January 27th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Atara Biotherapeutics presently has a consensus rating of “Buy” and an average target price of $34.17.

The company has a market cap of $641.91 million, a price-to-earnings ratio of -2.00 and a beta of 1.82. The firm has a fifty day moving average price of $9.87 and a 200 day moving average price of $14.13.

Atara Biotherapeutics (NASDAQ:ATRAGet Rating) last released its quarterly earnings data on Monday, February 28th. The biotechnology company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.36). The company had revenue of $7.55 million during the quarter, compared to analyst estimates of $47.75 million. Atara Biotherapeutics had a negative net margin of 1,672.28% and a negative return on equity of 103.05%. During the same period in the previous year, the company posted ($0.95) EPS. As a group, equities analysts expect that Atara Biotherapeutics, Inc. will post -3.39 earnings per share for the current fiscal year.

In other Atara Biotherapeutics news, CFO Utpal Koppikar sold 2,496 shares of the firm’s stock in a transaction on Monday, February 7th. The stock was sold at an average price of $14.46, for a total transaction of $36,092.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Jakob Dupont sold 5,000 shares of the firm’s stock in a transaction on Thursday, February 10th. The shares were sold at an average price of $16.00, for a total value of $80,000.00. The disclosure for this sale can be found here. Corporate insiders own 3.80% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. Macquarie Group Ltd. lifted its holdings in Atara Biotherapeutics by 326.1% during the 3rd quarter. Macquarie Group Ltd. now owns 3,311 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 2,534 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Atara Biotherapeutics during the first quarter worth $284,000. Point72 Hong Kong Ltd lifted its holdings in shares of Atara Biotherapeutics by 1,155.2% during the third quarter. Point72 Hong Kong Ltd now owns 7,845 shares of the biotechnology company’s stock worth $140,000 after buying an additional 7,220 shares in the last quarter. LPL Financial LLC acquired a new stake in shares of Atara Biotherapeutics during the third quarter worth $181,000. Finally, Teacher Retirement System of Texas acquired a new stake in shares of Atara Biotherapeutics during the third quarter worth $205,000.

About Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma.

Further Reading

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.